Nebulized Ensifentrine Suspension; 3 mg
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Overview
Nebulized Ensifentrine Suspension; 3 mg is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Nebulized Ensifentrine Suspension; 3 mg clinical trials
Explore related
Medical disclaimer. This page summarizes research about Nebulized Ensifentrine Suspension; 3 mg for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.